Hi, How Are You?
↻
Let's Get Started
Forgot Password?
Sign Up
EN
Home
Article
Events
All Events
Webinar
new!
Product & Disease
Product
Disease
Pharmacovigilance
Medical Calculator
new!
Education
MOOC
CDK
Multimedia
FAQ & Feedback
Discussions
About Us
Login
Register
Product
Profile
PRODUCTS
DISEASE
PHARMACOVIGILANCE
MEDCAL
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
TACERAL
BRANDED
Capecitabine is a non-cytotoxic fluoropyrimidine carbamate, which functions as an orally administered precursor of cytotoxic 5-FU.
Available at :
Share this article
Related
Articles
Serplulimab Approved for First-line Treatment of Extensive Stage Small Cell Lung Cancer (ES-SCLC) in the European Union
by dr. Dita Arccinirmala | 06 Feb 2025
Adjuvant Endocrine Therapy Plus OFS Still Provides Benefits in HR+ Breast Cancer Patients
by dr. Hastarita Lawrenti | 06 Feb 2023
Giving Oral Nutrition Supplements to Colorectal Cancer Post-surgery Patients, These are the Benefits
by dr. Dedyanto Henky Saputra | 22 Jul 2022
ASCO Recommendations Regarding Diet and Exercise for Cancer Patients
by Dr. Dedyanto Henky Saputro, M. Gizi, AIFO-K | 17 Jun 2022
TPC Induction Chemotherapy for Advanced Locoregional Nasopharyngeal Cancer Patients
by dr. Hastarita Lawrenti | 12 Apr 2022
Chemotherapy for breast cancer patients during pandemic
by Dr. Hastarita | 23 Mar 2022
Capecitabine Maintenance Therapy plus Best Supportive Care in Metastatic Nasopharyngeal Cancer Patients
by dr. Hastarita Lawrenti | 14 Mar 2022
Addition of Capecitabine to Adjuvant Chemotherapy for Early Stage Breast Cancer
by dr. Hastarita Lawrenti | 04 Feb 2022
Tislelizumab Therapy plus Chemotherapy is Beneficial for Patients with Recurrent or Metastatic Nasopharyngeal Cancer
by dr. Hastarita Lawrenti | 19 Jan 2022
Asciminib or Bosutinib in CML Patients with ≥ 2 Previous TKI
by Dr. Hastarita | 21 Dec 2021
×
Subscribe Status
Generals
Articles
CPD/CME & CDK
Events & Webinar
SAVE